FAPI PET for Lung Fibrosis

Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · May 3, 2022

Keywords

ClinConnect Summary

This clinical trial, called "FAPI PET for Lung Fibrosis," is exploring how a special imaging agent, called the FAPI tracer (68Ga-FAPI-46), behaves in the lungs of patients with interstitial lung disease (ILD). The study aims to see how much of this tracer gathers in both healthy and damaged lung tissues. This research could help doctors better understand ILD and improve diagnosis and treatment options for conditions like pulmonary fibrosis and drug-induced lung issues.

The trial is open to patients aged 18 and older who have been diagnosed with ILD through a CT scan. To participate, they either need to be starting a new medication for ILD or scheduled for a lung biopsy or surgery within three months. Participants will receive an injection of the FAPI tracer and will undergo one PET/CT scan and one high-resolution CT scan of their lungs. This study is being conducted by the Ahmanson Translational Theranostic Division at UCLA, and they are currently looking for a total of 30 participants. If you or someone you know is interested in learning more about this study, please reach out for more information.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Patients with ILD confirmed by CT at time of staging
• • Patients who have initiated or will initiate a new ILD medication with 3 months of enrollment OR Patients who are scheduled to undergo tissue biopsy or surgery of the lung
• • Patients are ≥ 18 years old at the time of the radiotracer administration
• • Patient can provide written informed consent
• • Exclusion criteria
• • Patient is pregnant or nursing
• • Patients with active infectious lung disease
• • Patients not expected to comply with the protocol requirements, not able to understand or follow trial procedures